TWiEVO 79: When the immune system is away, SARS-CoV-2 will play
Nels and Vincent discuss an analysis of the drivers of evolution of SARS-CoV-2 during chronic infections, indicating that a tradeoff exists between antibody evasion and fitness.
SARS-CoV-2
TWiV 914: COVID-19 clinical update #121 with Dr. Daniel Griffin
In COVID-19 clinical update #121, Dr. Griffin discusses age as a risk factor for severe disease, updated vaccine boosters for the fall, pediatric infection and antibody seroprevalence in Arkansas over the first year of the COVID-19 pandemic, all-cause maternal mortality in the United States before and during the pandemic, and the effect of 2-week interruption in methotrexate treatment and how it impacts vaccine immunity.
TWiV 911: Antibody can get vaccinated now
TWiV provides an update on hepatitis of unknown etiology in children, an experimental nanoparticle vaccine for Epstein-Barr virus, and minimal impact of bamlanivimab therapy on antiviral antibodies induced by vaccination. Hosts: Vincent Racaniello, Rich Condit, Kathy Spindler, and Brianne Barker Click arrow to playDownload TWiV 911 (76 MB .mp3, 127 min)Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Show …
TWiV 910: COVID-19 clinical update #119 with Dr. Daniel Griffin
In COVID-19 clinical update #119, Dr. Griffin reviews tixagevimab for infection prevention, ivermectin for outpatient infection treatment, symptom rebound after PAXLOVID treatment, bamlanivimab minimally impacting immune response to vaccination, in-hospital mortality among infection patients, residual viral antigen in patients following infection, usage of Casirvimab/Imdevimab and Remdesivir in infected patients with depleted B-cells, and rheumatic symptoms …
TWiV 910: COVID-19 clinical update #119 with Dr. Daniel Griffin Read More »
TWiV 905: COVID-19 clinical update #117 with Dr. Daniel Griffin
In COVID-19 clinical update #117, Dr. Griffin discusses duration of virus shedding, association between pre-exposure to steroids and infection outcome, post-infection subtypes, rehabilitation for post-acute infection, Tixagevimab/Cilgavimab for infection prevention, antibody prophylaxis and vaccination in kidney transplant recipients, remdesivir and bebtelovimab fact sheets for providers, the updated guidelines on treatment with Famotidine, Paxlovid rebound symptom characterizations, antigen test positivity duration, viral dynamics of variants and isolation, association of inflammation in CS fluid, and transmission dynamics in Ghana.
TWiV 902: Autoantibodies drive severe COVID-19
TWiV reviews recent cases of monkeypox, presence of SARS-CoV-2 RNA but not infectious virus in feces, and the association of autoantibodies to interferons with severe COVID-19.